首页 | 本学科首页   官方微博 | 高级检索  
检索        

大剂量顺铂分次给药治疗非小细胞肺癌的近期疗效及安全性的Meta分析
引用本文:韩丹,张晓晔,黄鲁众.大剂量顺铂分次给药治疗非小细胞肺癌的近期疗效及安全性的Meta分析[J].现代肿瘤医学,2016,0(23):3730-3734.
作者姓名:韩丹  张晓晔  黄鲁众
作者单位:中国医科大学附属盛京医院第四肿瘤科,辽宁 沈阳 110020
基金项目:辽宁省自然科学基金(编号2014021032)
摘    要:目的:采用Meta分析方法对顺铂分次给药治疗非小细胞肺癌的近期疗效及不良反应进行评价。方法:检索Pubmed、EMbase、Cochrane Library、中国知网CNKI全文数据库、维普数据库、万方数据库和中国生物医学文献数据库,查找建库初始至2016年4月公开发表的研究顺铂分次给药治疗非小细胞肺癌的临床随机对照试验。按照纳入与排除标准选择文献,质量评估,资料提取,采用RevMan 5.2软件进行Meta分析。结果:共纳入6篇中文RCT文献。Meta分析结果显示,顺铂分次给药组与单次给药组在近期疗效上无明显差异[OR=0.81,95%CI(0.57,1.15),P=0.24];顺铂分次给药组发生恶心与呕吐少于单次给药组[OR=0.45,95%CI(0.30,0.69),P=0.000 3];而发生骨髓抑制[OR=0.64,95%CI(0.40,1.01),P=0.06]、肾功能下降[OR=0.74,95%CI(0.30,1.82),P=0.51]和神经毒性[OR=0.38,95%CI(0.13,1.12),P=0.08],与单次给药组无明显差异。结论:大剂量顺铂分次给药,在不降低近期疗效的情况下,减轻了化疗相关性恶心和呕吐,值得广泛应用。

关 键 词:顺铂  分次给药  非小细胞肺癌  近期疗效  恶心和呕吐  Meta分析

Recent efficacy and safety of divided administration of high dose cisplatin in the treatment of non -small cell lung cancer:A Meta -analysis
Han Dan,Zhang Xiaoye,Huang Luzhong.Recent efficacy and safety of divided administration of high dose cisplatin in the treatment of non -small cell lung cancer:A Meta -analysis[J].Journal of Modern Oncology,2016,0(23):3730-3734.
Authors:Han Dan  Zhang Xiaoye  Huang Luzhong
Institution:The Fourth Oncology Department in Shengjing Hospital of China Medical University,Liaoning Shenyang 110020,China.
Abstract:Objective:To evaluate the recent efficacy and safety of divided cisplatin administration in the treatment of non -small cell lung cancer.Methods:Studies were identified by searching Pubmed,EMbase,Cochrane Library, CNKI,VIP,Wanfang and CBM by April 2016.Randomized clinical trials of divided cisplatin administration in the treatment of non -small cell lung cancer were included.Choose studies according to the inclusion and exclusion crite-ria,and evaluate quality retrieve data.Meta -analysis was performed for the results of studies by using RevMan 5.2 software.Results:Six studies were included.The results showed:There was no statistically significant difference on re-cent efficacy between the divided administration group and single administration groupOR =0.81,95%CI(0.57, 1.15),P =0.24].Nausea and vomiting in the divided administration group was significantly lower than that in the single administration groupOR =0.45,95%CI(0.30,0.69),P =0.000 3],but there was no statistically significant difference on bone marrow suppressionOR =0.64,95%CI(0.40,1.01),P =0.06],renal function declineOR =0.74,95%CI(0.30,1.82),P =0.51]and neurotoxicityOR =0.38,95%CI(0.13,1.12),P =0.08]between the two groups.Conclusion:Divided administration of high dose cisplatin,could reduce chemotherapy -induced nausea and vomiting,without reducing recent efficacy.It was worthy of wide application clinically.
Keywords:cisplatin  divided administration  non -small cell lung cancer  recent efficacy  nausea and vomiting  Me-ta -analysis
本文献已被 万方数据 等数据库收录!
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号